- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01100801
A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients (3G)
A Phase II Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients
This is an open, non-randomized, multicenter Phase II study evaluating cisplatin plus TS-1 or oxaliplatin plus TS-1 as first-line therapy in predicted 'responder' to platinum and fluoropyrimidine.
This study is planned in 3 centers in Singapore and Korea. A total of 30 subjects will be enrolled into each treatment arms. Each centers will recruit 15-25 subjects predicted to be 'responder' to platinum and fluoropyrimidine. The study will consist of a prescreening period, a screening period and a treatment period. A fresh tumour biopsy sample will be obtained during the prescreening period for gene expression profiling.
As this is a genomics guided trial, obtaining tissue biopsies is vital to the conduct of the trial.
Patients will have the primary in situ (requirement for entry into trial), endoscopic biopsy performed prior to 1st cycle.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gastric cancer is the world's second leading cause of cancer death. For patients with unresectable disease or recurrent disease after surgery, the main therapeutic option is chemotherapy. Chemotherapy can improve survival and quality of life in patients with advanced disease when compared with best supportive care alone.
Despite a large number of randomized trials, there is no consensus as to the best agent or regimen. In general, combination chemotherapy regimens provide higher response rates than do single agent, however, this translates into only a modest improvement in outcome with a trade off in increased treatment toxicities. The key challenge in managing patients with advanced gastric cancer is to identify the appropriate drugs for patients who might benefit for palliative chemotherapy.
Gastric cancer is a heterogeneous disease with differing chemosensitivities to anti-cancer drugs. Current selection of standard therapy is often empirical. Gene expression profiling has been shown to have the capability to dissect this heterogeneity allowing for sub-classification and risk-stratification of cancers according to their biological features and clinical outcome. Utilising gene expression data coupled with in-vitro, in-vivo or clinical response data is a promising strategy that may enable clinicians to match the right drug to the right patient.
The purpose of the study are:
- Assess the feasibility of genomic-guided therapy
- Evaluated treatment response of standard-of-care chemotherapy in an enriched patient groups defined as 'responder' based on genomic-guided therapy
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Wei Peng Yong, MRCP,MB ChB
- Phone Number: 65 6772 4670
- Email: Wei_Peng_Yong@nuhs.edu.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- National University Hospital
-
Contact:
- Wei Peng Yong, MRCP, MB ChB
- Phone Number: 65 6772 4670
- Email: Wei_Peng_Yong@nuhs.edu.sg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically documented locally advanced, metastatic or recurrent gastric cancer for which convention therapy of a platinum/fluoropyrimidine combination is indicated
- Predicted 'responder' to platinum and fluoropyrimidine based on tumour expression signature derived from in-vitro sensitivity array
- At least one measurable defined by RECIST
- Age >=21 years old
- Performance status (ECOG) 0-2
- Life expectancy >3 months
- No significant problems for oral intake and drug administration
- Adequate organ functions:
bone marrow function (ANC = 1,500/uL, Platelet = 100,000/ uL, Hb = 8.0 g/dl) renal function: serum creatinine = UNL (if serum creatinine > ULN, creatinine clearance should be = 60 mL/min) hepatic function (Total bilirubin < 2 x UNL and AST/ALT levels < 3 x ULN without liver metastasis, total bilirubin < 3x ULN and AST/ALT levels < 5 x ULN with liver metastasis)
- Recovery from relevant toxicity to previous treatment before study entry
- Ability to understand and willingness to sign a written informed consent before study entry
Exclusion Criteria:
- Prior chemotherapy for gastric cancer except neoadjuvant or adjuvant systemic therapy if terminated at least 6 months before the start of treatment in this study
- Prior radiotherapy was administered to target lesions selected for this study
- Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence)
- Presence of symptomatic or progressing CNS metastasis
- Serious illness or medical conditions:
Congestive heart failure (NYHA class III or IV), unstable angina or myocardial infarction within the past 3 months Hepatic cirrhosis (= Child class B) Psychiatric disorder that may interfere with protocol compliance Active infection
- Known hypersensitivity to platinum or fluoropyrimidine.
- Pregnant or lactating woman. Women of child bearing potential not using a contraceptive method
- Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential
- Any patients judged by the investigator to be unfit to participate in the study
- Predicted 'non-responder' to platinum and fluoropyrimidine based on tumour expression signature derived from in- vitro sensitivity array
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TS-1 with cisplatin
Chemotherapy injection (60mg/m2 cisplatin) will be given on day 1. 14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days. |
Other Names:
|
Experimental: TS-1 with oxaliplatin
Chemotherapy injection (100mg/m2 oxaliplatin) will be given on day 1. 14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days. |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate (RR)
Time Frame: 1 year
|
To determine the response rate of cisplatin/TS-1 and oxaliplatin/TS-1 combination in predicted 'responders'
|
1 year
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y, Yasuda Y, Nagai H, Shirasaka T. Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol. 2004 Jun;9(3):143-8. doi: 10.1007/s10147-004-0381-9.
- Koizumi W. Chemotherapy for advanced gastric cancer: review of global and Japanese status. Gastrointest Cancer Res. 2007 Sep;1(5):197-203.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GA01/01/10
- 2010/00064 (Other Identifier: NHG Domain Specific Review Board)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Gastric Cancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
National Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Adenocarcinoma of the Gastroesophageal Junction | Recurrent Breast Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Gastric Cancer | Recurrent Gastric CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditionsUnited States
-
Yonsei UniversityNot yet recruitingRecurrent/Metastatic Gastric CancerKorea, Republic of
-
Yonsei UniversityWithdrawnRecurrent/Advanced Gastric CancerKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedUnknownRecurrent Gastric Cancer | Advanced Metastatic Gastric CancerKorea, Republic of
-
Yonsei UniversityActive, not recruitingRecurrent/Metastatic Gastric CancerKorea, Republic of
-
Yonsei UniversityCompletedRecurrent or Metastatic Gastric CancerKorea, Republic of
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
Clinical Trials on TS-1 with cisplatin
-
Yonsei UniversityCompleted
-
Taiho Pharmaceutical Co., Ltd.Completed
-
National University Hospital, SingaporeRecruitingCancer | Liver DysfunctionSingapore
-
Yonsei UniversityCompleted
-
Kyungpook National University HospitalUnknownGastric CancerKorea, Republic of
-
Asan Medical CenterNational Cancer Center, Korea; Chonbuk National University Hospital; Samsung... and other collaboratorsCompletedAdvanced Gastric CancerKorea, Republic of
-
TTY BiopharmCompletedNon-small-cell Lung Cancer (NSCLC)Taiwan
-
Yonsei UniversityRecruitingGastric AdenocarcinomaKorea, Republic of
-
Min-Hee RyuCompletedGastric CancerKorea, Republic of
-
Peking UniversityTaiho Pharmaceutical Co., Ltd.Unknown